Accurate Alzheimer's disease (AD) detection remains challenging and often requires invasive or costly procedures. Blood-based metabolomic signatures offer a promising non-invasive approach. This study Show more
Accurate Alzheimer's disease (AD) detection remains challenging and often requires invasive or costly procedures. Blood-based metabolomic signatures offer a promising non-invasive approach. This study aimed to identify a serum metabolite panel and evaluate its performance alone and in combination with Baseline data from 594 participants in the Alzheimer's Disease Neuroimaging Initiative (237 AD, 357 CN) were analyzed. High-resolution serum metabolomics (Biocrates MxP® Quant 500) and A panel of 151 metabolites distinguished AD from CN with high accuracy (test-set AUC=0.90). Adding Integrating serum metabolomics with NCT00106899 and related ADNI phases. Show less